Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Wednesday.

A number of other analysts have also commented on NBIX. Piper Jaffray Companies set a $68.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a report on Wednesday, May 24th. J P Morgan Chase & Co set a $57.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a report on Wednesday, May 24th. Oppenheimer Holdings, Inc. set a $70.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a report on Wednesday, May 24th. Jefferies Group LLC reaffirmed a “buy” rating and set a $66.00 target price on shares of Neurocrine Biosciences in a report on Tuesday, May 30th. Finally, Leerink Swann lowered their target price on shares of Neurocrine Biosciences from $68.00 to $66.00 and set an “outperform” rating for the company in a report on Thursday, May 25th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and sixteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $67.69.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Shares of Neurocrine Biosciences (NASDAQ:NBIX) traded up 3.94% during trading on Wednesday, reaching $47.47. The company had a trading volume of 1,216,066 shares. The company’s market cap is $4.18 billion. The firm has a 50-day moving average of $48.73 and a 200-day moving average of $45.01. Neurocrine Biosciences has a 12-month low of $37.35 and a 12-month high of $55.38.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Tuesday, May 9th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by $0.23. During the same quarter last year, the business earned ($0.22) EPS. On average, equities research analysts anticipate that Neurocrine Biosciences will post ($2.46) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/06/21/neurocrine-biosciences-inc-nbix-upgraded-to-hold-at-bidaskclub.html.

In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 19,596 shares of Neurocrine Biosciences stock in a transaction on Wednesday, April 12th. The shares were sold at an average price of $50.42, for a total value of $988,030.32. Following the sale, the chief executive officer now directly owns 332,913 shares in the company, valued at approximately $16,785,473.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Corinne H. Nevinny sold 5,000 shares of Neurocrine Biosciences stock in a transaction on Friday, May 5th. The shares were sold at an average price of $53.98, for a total transaction of $269,900.00. Following the completion of the sale, the director now owns 34,603 shares in the company, valued at $1,867,869.94. The disclosure for this sale can be found here. Insiders sold a total of 104,360 shares of company stock worth $5,501,889 over the last quarter. Company insiders own 4.80% of the company’s stock.

A number of large investors have recently modified their holdings of NBIX. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Neurocrine Biosciences during the first quarter valued at about $2,083,000. Goldman Sachs Group Inc. raised its stake in shares of Neurocrine Biosciences by 126.0% in the first quarter. Goldman Sachs Group Inc. now owns 1,743,949 shares of the company’s stock valued at $75,513,000 after buying an additional 972,434 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Neurocrine Biosciences during the first quarter valued at about $4,330,000. Janus Capital Management LLC raised its stake in shares of Neurocrine Biosciences by 85.0% in the first quarter. Janus Capital Management LLC now owns 4,359,384 shares of the company’s stock valued at $188,759,000 after buying an additional 2,002,899 shares during the last quarter. Finally, Macquarie Group Ltd. raised its stake in shares of Neurocrine Biosciences by 22.8% in the first quarter. Macquarie Group Ltd. now owns 775,890 shares of the company’s stock valued at $33,596,000 after buying an additional 143,825 shares during the last quarter. Hedge funds and other institutional investors own 95.90% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.